Wirtschaft & Industrie
CDEX to Showcase the ValiMed(TM) G4 System at the 47th ASHP Midyear Clinical Meeting and Exhibition
© Marketwire 2012
(PR-inside.com 28.11.2012 15:26:31)
TUCSON, AZ -- (Marketwire) -- 11/28/12 -- CDEX Inc. (OTCQB: CDEX), a leading developer of chemical detection products using patented technologies for use in healthcare, safety and security markets, today announced the company will participate at the 47th Annual Midyear ASHP Clinical Meeting and Exhibition to demonstrate the ValiMed G4 medication safety, and narcotic detection system. The ASHP conference is being held December 2-6, 2012 at the Mandalay Bay Hotel and Casino in Las Vegas, NV. The ValiMed G4 drug validation system will be showcased at booth 2107 at the exhibition.
"This is the second year for us to demonstrate the capabilities of the ValiMed G4 at the ASHP Midyear conference. By year's end, we expect to have placed our initial units. These placements originated from last year's event, which in-turn produced a number of contracts. We expect the event this year to be even better, with numerous private showings already scheduled," stated Jeff Brumfield, chairman and chief executive officer of CDEX.
The ValiMed G4 drug system helps healthcare providers ensure patient safety and control costs by reducing medication errors. The patented & patent pending detection process identifies drug strengths in real-time, validating proper dose / concentration of high-risk compounded medications and treatment solutions. The VG4 device will help healthcare facilities with Joint Commission compliance requirements and USP 797 guidelines for compounding sterile preparations (CSPs), and can integrate with electronic medical record (EMR) platforms.
CDEX's VG4 significantly raises the bar for patient medication safety and pharmaceutical drug loss prevention. The Valimed G4 provides cutting edge features and benefits over existing systems available in the market. In addition to validating high-risk medications before leaving the clinical or pharmacy environment, the ValiMed G4 will also monitor and discourage the diversion of controlled substances by validating the returned or unused narcotics from patient treatment areas or surgery suites. Other applications for the ValiMed G4 system include counterfeit medication monitoring, regulatory compliance and training of clinical and pharmacy personnel.
The American Society of Health-System Pharmacists (ASHP) Midyear Clinical Meeting and Exhibition is the largest gathering of pharmacists in the world. With its focus on improving patient care, the conference is attended by more than 20,000 pharmacy professionals from 86 countries. For over four decades, the ASHP Midyear Clinical Meeting has provided health-system pharmacy practitioners with a venue for updating their knowledge, networking with colleagues, enhancing their skills, and learning about the latest products and technologies available in the market. For more information about the event please visit: http://www.ashp.org/Midyear2012 : .
About CDEX Inc.
CDEX develops, manufactures and globally distributes products to the healthcare, safety and security markets. The ValiMed product line provides life-saving validation of high-risk medications and pharmacy returned narcotics. The ID2 product line detects trace amounts of illegal drugs, such as methamphetamine. CDEX expects to advance its patented technologies to serve additional markets in the future where its proprietary products can be launched. To learn more about CDEX please visit: www.cdex-inc.com : .
Safe Harbor Statement
Non-historical statements are forward-looking, as defined in federal securities laws, and generally can be identified by words such as "expects," "plans," "may," "believes," "should," "intends," and similar words. These statements pose risks that cannot be accurately predicted. Consequently, results may differ materially from those expressed or implied. Such risks and uncertainties include, without limitation, the effectiveness, profitability and marketability of products, the protection of intellectual property and proprietary information, and other risks detailed periodically in filings with the SEC. There is no obligation to update any forward-looking statements.
Add to Digg : Bookmark with del.icio.us : Add to Newsvine :
Chairman and CEO
Email Contact : docid: 12959292.nitf -->
(C) Das Copyright für sämtliche Pressemeldungen und Bilder, die mit Marketwire gekennzeichnet sind und auf PR-inside.com publiziert werden, obliegt der Agentur Marketwire. Dieser Artikel darf ohne schriftliche Genehmigung der Agentur Marketwire weder kopiert noch veröffentlicht werden. Wenn Sie Fragen zu den veröffentlichten Meldungen haben, kontaktieren Sie bitte Marketwire unter der Internetadresse (http://www.marketwire.com/).